These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

667 related items for PubMed ID: 15877299

  • 21. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
    Hogue JC, Lamarche B, Deshaies Y, Tremblay AJ, Bergeron J, Gagné C, Couture P.
    Metabolism; 2008 Feb; 57(2):246-54. PubMed ID: 18191056
    [Abstract] [Full Text] [Related]

  • 22. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
    Demetriou D, Shabpar A, Böhmig G, Schmaldienst S, Hörl WH, Watschinger B.
    Wien Klin Wochenschr; 2000 Apr 21; 112(8):358-61. PubMed ID: 10849941
    [Abstract] [Full Text] [Related]

  • 23. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.
    Hogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagné C, Couture P.
    Metabolism; 2008 Mar 21; 57(3):380-6. PubMed ID: 18249211
    [Abstract] [Full Text] [Related]

  • 24. Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate.
    Wu TJ, Ou HY, Chou CW, Hsiao SH, Lin CY, Kao PC.
    Ann Clin Lab Sci; 2007 Mar 21; 37(2):158-66. PubMed ID: 17522372
    [Abstract] [Full Text] [Related]

  • 25. The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia.
    Koter M, Broncel M, Chojnowska-Jezierska J, Klikczynska K, Franiak I.
    Eur J Clin Pharmacol; 2002 Nov 21; 58(8):501-6. PubMed ID: 12451426
    [Abstract] [Full Text] [Related]

  • 26. Effect of atorvastatin and pravastatin on serum C-reactive protein.
    Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Taylor AJ.
    Am Heart J; 2003 Feb 21; 145(2):e8. PubMed ID: 12595863
    [Abstract] [Full Text] [Related]

  • 27. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
    Avellone G, Di Garbo V, Abruzzese G, Campisi D, De Simone R, Raneli G, Licata G.
    Int Angiol; 2006 Mar 21; 25(1):26-34. PubMed ID: 16520721
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S, Rajeev E, Tharakan JA, Titus T, Ajit Kumar VK, Sivasankaran S, Krishnamoorthy KM, Nair K.
    Indian Heart J; 2008 Mar 21; 60(3):215-22. PubMed ID: 19240310
    [Abstract] [Full Text] [Related]

  • 29. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).
    Alrasadi K, Awan Z, Alwaili K, Ruel I, Hafiane A, Krimbou L, Genest J.
    Am J Cardiol; 2008 Nov 15; 102(10):1341-7. PubMed ID: 18993152
    [Abstract] [Full Text] [Related]

  • 30. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.
    Am J Geriatr Pharmacother; 2007 Sep 15; 5(3):185-94. PubMed ID: 17996658
    [Abstract] [Full Text] [Related]

  • 31. Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
    Avisar I, Brook JG, Wolfovitz E.
    Eur J Intern Med; 2008 May 15; 19(3):203-8. PubMed ID: 18395165
    [Abstract] [Full Text] [Related]

  • 32. A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia.
    Zhu J, Ye P.
    Chin Med J (Engl); 2003 Jun 15; 116(6):840-3. PubMed ID: 12877791
    [Abstract] [Full Text] [Related]

  • 33. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia.
    Paragh G, Törocsik D, Seres I, Harangi M, Illyés L, Balogh Z, Kovács P.
    Curr Med Res Opin; 2004 Aug 15; 20(8):1321-7. PubMed ID: 15324535
    [Abstract] [Full Text] [Related]

  • 34. Non-high-density lipoprotein cholesterol: a target of lipid-lowering in dialysis patients.
    Wanner C, Krane V.
    Am J Kidney Dis; 2003 Mar 15; 41(3 Suppl 1):S72-5. PubMed ID: 12612957
    [Abstract] [Full Text] [Related]

  • 35. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis.
    Kuryata OV, Yegorova YV.
    Kardiol Pol; 2006 Jan 15; 64(1):44-8; discussion 49-50. PubMed ID: 16444629
    [Abstract] [Full Text] [Related]

  • 36. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
    Rouleau J.
    Am J Med; 2005 Dec 15; 118 Suppl 12A():28-35. PubMed ID: 16356805
    [Abstract] [Full Text] [Related]

  • 37. [Pleiotropic effects of micronized fenofibrate in patients with combined hyperlipidemia].
    Okopień B, Cwalina Ł, Haberka M, Kowalski J, Zieliński M, Szwed Z, Kalina Z, Herman ZS.
    Pol Merkur Lekarski; 2002 Dec 15; 13(78):465-9. PubMed ID: 12666442
    [Abstract] [Full Text] [Related]

  • 38. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
    Deedwania PC, Hunninghake DB, Bays HE, Jones PH, Cain VA, Blasetto JW, STELLAR Study Group.
    Am J Cardiol; 2005 Feb 01; 95(3):360-6. PubMed ID: 15670545
    [Abstract] [Full Text] [Related]

  • 39. hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels A clinical investigation.
    Ansell BJ, Watson KE, Weiss RE, Fonarow GC.
    Heart Dis; 2003 Feb 01; 5(1):2-7. PubMed ID: 12549983
    [Abstract] [Full Text] [Related]

  • 40. Achieving lipid goals in real life: the Dutch DISCOVERY study.
    Bots AF, Kastelein JJ, Discovery Netherlands Investigators.
    Int J Clin Pract; 2005 Dec 01; 59(12):1387-94. PubMed ID: 16351669
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.